The company's India sales were at Rs 1,781.5 crore (up 6.7% YoY) while International sales were at Rs 760.4 crore (down 3.8% YoY) in the first quarter.
EBITDA declined 65.7% YoY to Rs 203.2 crore in Q1 FY23. EBITDA margin was at 7.9% as on 30 June 2022 as against 21.7% as on 30 June 2021.
R&D expenses for the quarter was Rs 132 crore, or 5.1% of total revenue from operations compared to Rs 118.3 crore in Q1 FY22 at 4.3% of total revenue from operations.
During the quarter, the company filed 3 abbreviated new drug applications (ANDAs) with the US FDA and received 4 approvals (including 1 tentative approval).
As on 30 June 2022, the company filed a total of 164 ANDAs and 2 new drug applications (NDA) with the USFDA. Of these, it has received approvals for 124 ANDAs (including 13 tentative approvals) and 2 NDAs.
Sandeep Singh, managing director of Alkem, said, “We are starting the new fiscal year on a positive note, with yet another market beating performance in domestic market adjusting for huge base of last year [CAGR of 13.4%, Q1FY20-Q1FY23]. However, headwinds from price erosion in US market and inflationary environment has impacted margins for the quarter. As we move ahead, we remain focused on our journey of expanding margins through productivity improvement and various cost optimization initiatives across the organization. Our biosimilar franchise is shaping up well and we are looking forward to some exciting launches going ahead.”
Alkem is a pharmaceutical company with global operations. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
The scrip fell 0.47% to currently trade at Rs 3,137.95 on the BSE.
Powered by Capital Market - Live News
Beware of fraudulent tips, unauthenticated news and advice on stock market.
At BOB Capital, your account security is our topmost priority. Beware of receiving fraudulent communications, unauthenticated trading tips and unsolicited calls on trading in stocks from unverified sources, received through Whatsapp, Telegram, SMS, Calls, etc and take an informed decision before investing.
What should you do if you receive a trading tip over phone or SMS?
Report unsolicited messages to the Stock Exchange on +91 8291833676 or on designated email id i.e. feedbk_invg@nse.co.in. Please visit here to understand better.
Valued Customer,
BOB Capital Markets Limited (BOBCaps) is firmly committed to the safety of your wealth. We would like to bring to your notice certain precautions that you certainly must take against potential tele-fraudsters/ unscrupulous and unregistered portfolio managers:
ALWAYS AVOID
Certain tele-fraudsters / unscrupulous and unregistered portfolio managers call customers or SMS them on the pretext of providing investment tips and lure them to invest through their bogus firms by promising huge profits. Such deceitful callers ask the customer to share his/her login credentials with passwords to allow trading in their accounts, assuring huge returns. Often trades done in the customer’s accounts are far from the best interest of the customers. Holdings of customers are often sold and with the funds, trades are then placed in illiquid securities at unrealistic prices. At times, the holdings of customers are sold at prices detrimental to the customer.
The so-called “portfolio manager” assures profits, which naturally does not materialize. Customers are deceived into providing access to their trading accounts, thereby allowing such fraudsters access to funds and securities available to execute trades, injurious to the customer’s interest.
We would like to caution you against such fraudulent calls and SMSes and urge you to be alert. Follow the golden rule:
Do not share your Login Credentials or Passwords with anybody
BOBCaps employees / representatives never ask for your password.